Glenmede Trust’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $282M | Sell |
306,828
-10,790
| -3% | -$10.9M | 1.38% | 12 |
|
|
2025
Q4 | $341M | Buy |
+317,618
| New | +$304M | 1.62% | 9 |
|
|
2025
Q1 | $258M | Sell |
311,963
-16,891
| -5% | -$14.1M | 1.38% | 8 |
|
|
2024
Q4 | $254M | Sell |
328,854
-27,442
| -8% | -$22.7M | 1.3% | 10 |
|
|
2024
Q3 | $316M | Sell |
356,296
-5,297
| -1% | -$4.76M | 1.51% | 6 |
|
|
2024
Q2 | $327M | Sell |
361,593
-6,185
| -2% | -$4.95M | 1.66% | 6 |
|
|
2024
Q1 | $286M | Sell |
367,778
-27,028
| -7% | -$19.2M | 1.43% | 6 |
|
|
2023
Q4 | $230M | Sell |
394,806
-14,845
| -4% | -$8.67M | 1.19% | 8 |
|
|
2023
Q3 | $220M | Sell |
409,651
-24,757
| -6% | -$12.8M | 1.26% | 8 |
|
|
2023
Q2 | $149M | Hold |
434,408
| – | – | 0.85% | 19 |
|
|
2023
Q1 | $149M | Sell |
434,408
-14,464
| -3% | -$4.88M | 0.85% | 19 |
|
|
2022
Q4 | $164M | Sell |
448,872
-5,057
| -1% | -$1.79M | 0.96% | 14 |
|
|
2022
Q3 | $147M | Buy |
453,929
+12,360
| +3% | +$3.92M | 0.93% | 13 |
|
|
2022
Q2 | $143M | Sell |
441,569
-8,487
| -2% | -$2.55M | 0.84% | 16 |
|
|
2022
Q1 | $129M | Sell |
450,056
-43,477
| -9% | -$11.2M | 0.63% | 29 |
|
|
2021
Q4 | $136M | Sell |
493,533
-8,491
| -2% | -$2.15M | 0.65% | 27 |
|
|
2021
Q3 | $116M | Sell |
502,024
-8,177
| -2% | -$2.02M | 0.6% | 30 |
|
|
2021
Q2 | $117M | Sell |
510,201
-25,801
| -5% | -$5.18M | 0.61% | 29 |
|
|
2021
Q1 | $100M | Buy |
536,002
+1,817
| +0.3% | +$355K | 0.54% | 38 |
|
|
2020
Q4 | $90.2M | Buy |
534,185
+38,809
| +8% | +$5.79M | 0.5% | 47 |
|
|
2020
Q3 | $73.3M | Sell |
495,376
-6,529
| -1% | -$1.01M | 0.44% | 57 |
|
|
2020
Q2 | $82.4M | Sell |
501,905
-17,168
| -3% | -$2.64M | 0.5% | 51 |
|
|
2020
Q1 | $68.2M | Hold |
519,073
| – | – | 0.31% | 83 |
|
|
2019
Q4 | $68.2M | Sell |
519,073
-298,422
| -37% | -$34.6M | 0.31% | 83 |
|
|
2019
Q3 | $91.4K | Sell |
817,495
-69,213
| -8% | -$7.71M | 0.42% | 58 |
|
|
2019
Q2 | $98.2K | Sell |
886,708
-77,311
| -8% | -$9.1M | 0.43% | 54 |
|
|
2019
Q1 | $125K | Sell |
964,019
-141,725
| -13% | -$17.2M | 0.57% | 38 |
|
|
2018
Q4 | $128K | Buy |
1,105,744
+22,557
| +2% | +$2.52M | 0.62% | 28 |
|
|
2018
Q3 | $116M | Sell |
1,083,187
-18,033
| -2% | -$1.8M | 0.47% | 41 |
|
|
2018
Q2 | $94M | Buy |
1,101,220
+385,266
| +54% | +$31.6M | 0.42% | 57 |
|
|
2018
Q1 | $60.5M | Hold |
715,954
| – | – | 0.25% | 95 |
|
|
2017
Q4 | $60.5M | Sell |
715,954
-14,814
| -2% | -$1.26M | 0.25% | 95 |
|
|
2017
Q3 | $62.5M | Sell |
730,768
-17,674
| -2% | -$1.45M | 0.27% | 90 |
|
|
2017
Q2 | $63M | Hold |
748,442
| – | – | 0.3% | 86 |
|
|
2017
Q1 | $63M | Sell |
748,442
-142,951
| -16% | -$11.4M | 0.3% | 86 |
|
|
2016
Q4 | $65.6M | Sell |
891,393
-14,899
| -2% | -$1.11M | 0.36% | 68 |
|
|
2016
Q3 | $72.7M | Sell |
906,292
-21,087
| -2% | -$1.69M | 0.41% | 52 |
|
|
2016
Q2 | $73M | Buy |
927,379
+20,095
| +2% | +$1.51M | 0.44% | 45 |
|
|
2016
Q1 | $65.3M | Buy |
907,284
+30,962
| +4% | +$2.34M | 0.42% | 53 |
|
|
2015
Q4 | $73.8M | Buy |
876,322
+11,181
| +1% | +$928K | 0.5% | 41 |
|
|
2015
Q3 | $72.4M | Sell |
865,141
-22,463
| -3% | -$1.9M | 0.53% | 33 |
|
|
2015
Q2 | $74.1M | Buy |
887,604
+3,698
| +0.4% | +$282K | 0.53% | 29 |
|
|
2015
Q1 | $64.2M | Sell |
883,906
-36,291
| -4% | -$2.58M | 0.47% | 35 |
|
|
2014
Q4 | $63.5M | Sell |
920,197
-14,170
| -2% | -$956K | 0.5% | 33 |
|
|
2014
Q3 | $60.6M | Sell |
934,367
-195,586
| -17% | -$12.4M | 0.53% | 35 |
|
|
2014
Q2 | $70.2M | Buy |
1,129,953
+102,029
| +10% | +$6.09M | 0.63% | 26 |
|
|
2014
Q1 | $60.5M | Buy |
1,027,924
+554,735
| +117% | +$31M | 0.56% | 36 |
|
|
2013
Q4 | $24.1M | Sell |
473,189
-991
| -0.2% | -$49.6K | 0.25% | 89 |
|
|
2013
Q3 | $23.9M | Sell |
474,180
-26,688
| -5% | -$1.4M | 0.28% | 82 |
|
|
2013
Q2 | $24.6M | Buy |
+500,868
| New | +$27.3M | 0.31% | 67 |
|
Other funds holding LLY
VCM
VPM
Glenmede Trust's LLY Position: Q1 2026 in Review
Glenmede Trust reduced its Eli Lilly (LLY) stake by 3.4% in Q1 2026, selling an estimated $10.9M and leaving 306,828 shares worth $282M. The position accounts for 1.38% of the portfolio, ranked #12.
Glenmede Trust first reported a position in LLY in Q2 2013 and has held it in 50 quarters since. The position peaked at $341M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Glenmede Trust held 306,828 shares of Eli Lilly worth $282M as of Q1 2026.
- Glenmede Trust sold 10,790 Eli Lilly shares in Q1 2026, an estimated $10.9M.
- Eli Lilly made up 1.38% of Glenmede Trust's portfolio in Q1 2026, its #12 holding.
- Glenmede Trust first reported a position in Eli Lilly in Q2 2013 and has held it in 50 quarters since.
- Glenmede Trust's Eli Lilly position peaked at $341M in Q4 2025.
- 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.